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Abstract: Obesity represents a major under-recognized preventable risk factor for cancer development
and recurrence, including breast cancer (BC). Healthy diet and correct lifestyle play crucial role for
the treatment of obesity and for the prevention of BC. Obesity is significantly prevalent in western
countries and it contributes to almost 50% of BC in older women. Mechanisms underlying obesity,
such as inflammation and insulin resistance, are also involved in BC development. Fatty acids are
among the most extensively studied dietary factors, whose changes appear to be closely related
with BC risk. Alterations of specific ω-3 polyunsaturated fatty acids (PUFAs), particularly low
basal docosahexaenoic acid (DHA) levels, appear to be important in increasing cancer risk and its
relapse, influencing its progression and prognosis and affecting the response to treatments. On the
other hand, DHA supplementation increases the response to anticancer therapies and reduces the
undesired side effects of anticancer therapies. Experimental and clinical evidence shows that higher
fish consumption or intake of DHA reduces BC cell growth and its relapse risk. Controversy exists
on the potential anticancer effects of marine ω-3 PUFAs and especially DHA, and larger clinical
trials appear mandatory to clarify these aspects. The present review article is aimed at exploring the
capacity of DHA in controlling obesity-related inflammation and in reducing insulin resistance in BC
development, progression, and response to therapies.
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1. Introduction
Relation between Obesity, Insulin-Resistance, Inflammation, and Breast Cancer Development
Research on modifiable risk factors for mortality in breast cancer (BC) [1], including the role of
diet, has received increasing intensive attention by researchers worldwide [2], as they linearly affect
the prognosis of the disease.
Obesity represents a major under-recognized preventable risk factor for cancer development
and mortality and it increases cancer risk, including BC development [3]. Risk factors related to
diet, particularly obesity, and low physical activity are often underestimated in assessing BC risk.
The impact of obesity on the incidence and evolution of BC is not completely developed, due to multiple
confounding factors, including biological differences of cancer subtypes [4]. During pre-menopause
period, the subtype aggressive and estrogen receptor (ER) negative BC is more prevalent, whereas
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ER positive tumor subtypes are more frequent among post-menopausal women. Effects of obesity in
postmenopausal women may be mediated by endogenous sex hormones (high levels of circulating
estrogens and decreased levels of sex hormone binding globulin) [5,6]. This condition suggests that
obesity is considered a relevant risk factor in post-menopausal BC. Plasma estrogen levels are increased
in obese women and they are associated with almost a two-fold increased risk for BC development in
postmenopausal phase. Moreover, aromatase expression is four to five times higher in BC tissue with
respect to non-neoplastic areas of the same mammary gland [5]. In this light, estrogen concentrations
of the mammary tissue resulted to be up to 50 times greater compared to plasma levels in healthy
women in postmenopause. This condition has been demonstrated to be a crucial determinant in BC
proliferation [7,8].
Instead, obesity in premenopause enhances the risk for developing the subtype of BC hormone
receptor-negative [9,10].
This evidence supports that, independently from the hormonal derangements, obesity negatively
influences BC risk, which is in part related to inflammation, insulin resistance and hyperinsulinemia
related to obesity, and in part to hormonal interactions between cell types of the mammary gland [4].
Dietary polyunsaturated fatty acids (PUFAs) have been considered to play a key role in the
pathophysiology of BC malignancy. Recent evidences [4,11] indicate that omega (ω)-3 PUFAs,
including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), potentially reduce the
circulating concentrations of eicosanoids produced byω-6 PUFAs pathway [12] (Table 1). Moreover,
the cytotoxic environment generated byω-3 PUFAs has been shown to induce apoptosis and reduce
cell proliferation in BC cells [12,13]. Long-chain ω-3 PUFAs showed high capability to sensitize BC
cells to chemo- and radio-therapy, and thus potentially improve treatment efficacy, suggesting thatω-3
PUFAs oral intake, for which fish is the most important dietary source, might provide improvement of
survival among women with BC [13].
Moreover, ω-3 PUFAs may be useful in a pan-anti-inflammatory approach to mitigate the
inflammatory interactions of obesity on mammary tissue and subsequently to reduce tumorigenesis.
It has been documented that increased intake ofω-3 PUFA, and especially of DHA, might reduce the
incidence of BC associated to obesity. An American study found that higher intake of EPA and DHA
from fish was associated with lower BC relapse and mortality [14].
High intake of ω-3 PUFAs is related to lower concentrations of proinflammatory biomarkers,
i.e., interleukin (IL)-1, IL-6, tumor necrosis factor (TNF)-α, C reactive protein (CRP), and to higher
concentrations of anti-inflammatory cytokines, i.e., IL-10 (Table 1) [11,15,16].
In addition, experimental data suggest a strong tumor-enhancing effect of ω-6 PUFAs and
protective effects ofω-3 PUFAs on BC development [17]. Altering the balance between dietaryω-3
and ω-6 PUFAs has received attention as an approach for disease prevention, and tailored dietary
intervention may be indicated as a promising tool to reduce BC risk [17].
The aim of the present article is to explore the role of DHA in BC development, progression
and response to therapies. In particular, we focus on DHA capacity in controlling obesity-related
inflammation, as well as insulin resistance in BC.
2. Relation between Overweight and Obesity during and after Treatment for BC and the Relative
Risk of Recurrence
Obesity is a risk factor not only in influencing BC incidence, but also affecting poor clinical
outcomes during and after therapies [18], and it is predictive of increased all-cause mortality [3].
Despite the higher survival rates in the last decades, BC survivors remain at considerable high risk of
recurrence, as well as new primary BC, and the risk of mortality is higher compared to women without
a prior diagnosis of BC [19]. Based on the available observational studies, patients who are overweight
or obese at the diagnosis of BC, or who gain weight during therapies and follow-up, have a higher
risk of relapse or mortality with respect to patients who do not increase their body weight after the
diagnosis of BC [20–22]. Hormonal derangements, which are directly linked to the presence of obesity,
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and specifically the increased conversion of androgens to estrogens in peripheral adipose tissue, may
play a crucial role in enhancing BC growth [1,23].
Studies documented that weight gain during BC treatments decreases the survival rate and
increases the risk of recurrence [18,22,24].
Heideman et al. in a retrospective study conducted in Netherlands on patients treated for
BC showed a significant increase in body weight occurred since the first year after the diagnosis.
The highest gain of body weight in the five years after diagnosis was observed in patients who
underwent combined systemic chemotherapy and endocrine therapy [24]. Rooney et al. confirmed that
weight gain and changes in body composition are common during the first year after the diagnosis of
BC [22], and that these conditions are associated with a poorer prognosis and poorer overall survival
of BC patients [22]. Studies confirmed the association between BC and body weight gain for obese
patients and, in particular, a risk of recurrence almost two times greater and a risk of death at 10-year
follow-up greater with respect to patients maintaining usual body weight [18]. These data link obesity
to BC mortality. In addition, weight gain contributes to the risk of comorbidities such as diabetes,
cardiovascular disease, and depression [22].
The suggested mechanisms of weight gain after BC diagnosis and during cancer treatments
include changes of the hormonal status, decreased physical activity, increased intakes, and low basal
metabolic rate [21,23]. Increased circulating levels of leptin, insulin, and insulin-like growth factors
(IGF-1) promote tumor cell proliferation, negatively affecting the prognosis of BC. In overweight
and obese women the higher circulating levels of IGF-1 activate the phosphatidylinositol-3-kinases
(PI3K)/Protein kinase B (Akt) pathway [24]. On the contrary, several studies indicate an increased
overall survival in patients who are physically active after BC diagnosis [25,26], showing that physical
activity and weight maintenance are associated with reduced BC recurrence and mortality [27].
An improvement in quality of life has been documented as a result of practicing aerobic exercise
during and after therapies for BC. Physical activity improves mood and functional capacity, and
reduces fatigue and nausea. Moreover, lifestyle interventions aimed at avoiding weight gain and
increasing or maintaining a quite good level of physical activity, reduce BC incidence and ameliorate
prognosis. These effects were associated with the modulation of inflammatory mediators, insulin,
IGF-1 and estrogens [21].
3. Effect ofω-3 PUFAs and DHA on Inflammation in BC
Although hormonal modifications seem to play a driving role in breast carcinogenesis, the
cytokines production and the consequent increased inflammatory status are recognized as clinically
relevant features during BC growth and progression [28,29].
Chronic inflammation contributes to cancer growth and progression, playing a major role in the
neoplastic process. Almost 20% of tumors are associated with inflammation [30]. Considering the
elevated inflammatory state, which is present in obesity [31,32], the production of adipose tissue
inflammatory mediators related to obesity could exacerbate tumorigenic effects associated with
inflammation [4]. High body fat content determines insulin-resistance and increased circulating
concentrations of insulin-like growth factor (IGF) and adipokines, including leptin and adiponectin,
and abnormal values of TNF-α and IL-6 [33]. Insulin-like growth factor, IL-6, and leptin promote
neoangiogenesis and trascriptional factors and increase aromatase activity determining production of
estrogens [23]. It is known that leptin concentrations are directly proportional to total body fat [16]
and high leptin levels are related with greater risk of BC growth and progression [34]. Most of these
adipokines are upregulated in overweight and obese BC patients and modulate intracellular pathways
influencing cell malignant transformation associated with inflammation [35].
Observational studies linked inflammation to imbalance of dietary intake of ω-3 and ω-6
PUFAs [2] (Figure 1), and specifically a higher intake of ω-3 fatty acids is associated with lower
levels of proinflammatory cytokines (IL-2, IL-6, TNF-α) and with higher anti-inflammatory patterns
(IL-10, TGF-β) [16]. Imbalance of dietary intake of ω-3 and ω-6 PUFAs (also expressed as ω-6/ω-3
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ratio) reached with a high ω-6 PUFAs diets is associated with increased adipokines levels, higher
proinflammatory cytokines secretion, and hyperinsulinemia, which represent factors all contributing
to chronic inflammation [1,23]. Dietary ω-6 PUFAs increase the eicosanoids synthesis, increasing
inflammatory status and the immune response [2]. These events condition cell angiogenic and
proliferation properties [2]. The ω-6/ω-3 ratio may be a stronger predictor of inflammation with
respect to the fatty acid alone [16]. Alfano et al. [16] documented in a prospective study on more than
600 BC survivor women, a significant linear association between inflammatory markers, particularly
CRP, andω-6 andω-3 intake. Women with the highestω-6/ω-3 ratio who were not supplemented
withω-3, had the highest serum CRP levels, whereas women with the lowestω-6/ω-3 ratio and who
were assumingω-3 supplements showed the lowest serum CRP levels [16].
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In the recent years, western diets are significantly enriched inω-6 PUFAs content, determining
an imbalance in theω-6/ω-3 PUFA ratio. Increasedω-6 PUFA co tents and a highω-6/ω-3 ratio up to
a 16:1 ratio, have been indicate to favor th development of everal diseases, in ludi g cardiovascular
disease a d different types of tumor, whereas higherω-3 PUFAs concentrations have been shown to
exert protective effects [36].
Experimental studies showed that dietary supplementation of ω-3 PUFAs was related to reduced
adipose tissue inflammation and increased insulin sensitivity in obese mice [37], highlighting that
ω-3 PUFAs might be useful in reducing obesity-associated inflammation, metabolic derangements
during cancer [38], and tumorigenic risk [28,39]. Similarly, clinical studies conducted in overweight
patients confirmed the anti-tumorigenic effects mediated by ω-3 PUFAs, showing that ω-3 PUFA
supplementation up-regulated the expression of genes i volv in cell cycle control [40].
In human clinical trials, die ary ω-3 PUFAs increased adiponectin levels in obes and overweight
subjects, demonstrating the potential utility of ω-3 PUFA to restore adiponectin fu ction and to
stimulate its anti-inflammatory properties [4], and consequently the anti-tumorigenic effects of this
adipokine [41].
Nevertheless, a randomized trial in healthy young adults, providing increasing doses of
EPA + DHA up to 1.8 g/day for five months, found a marginal decrease in TNF-α levels and no change
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in IL-6 levels, documenting no effect of marine PUFAs on circulating inflammatory molecules [42].
However, we acknowledge that healthy adults are unlikely to have high levels of inflammatory
markers, hence less likelihood of showing a response. In this light, we found several positive results,
when considering the effects of omega-3 fatty acids administration on inflammation associated with
several diseases [43], including obesity [44].
Also, it is known that the effects of ω-3 PUFAs, which are able to inhibit cancer development
and progression, are related to the number of their skipped dienes [45]. Studies documented that the
negative control of cancer cells proliferation was more evident during a treatment with DHA, than
with alpha-linolenic acid or with EPA [46]. This indicates that PUFAs need a peroxidation process to
become active [47]. Lipids peroxidation, which is followed by secondary metabolites transformation,
represents an important pathway able to reduce cancer cell proliferation rate [48]. A synthesis of
non-enzymatic metabolites, as neuroprostanes or isoprostanes [49], might explain the anti-proliferative
action of DHA in BC (Figure 1). Neuroprostanes and isoprostanes are able to decrease cell growth
through damaging cell membranes, by altering membrane composition and structure. These changes
in cell membranes can inactivate its transport systems and/or enzymes activity [48,49]. In addition,
metabolites of lipid peroxidation reduce cancer cell proliferation through the inactivation of DNA
polymerase reactions, inducing intramolecular linkages between nucleic acids and proteins [49].
Further investigations will need to address the role of additional markers of inflammation,
including cellular adhesion molecules, and of lipid peroxidation to better clarify the clinical effects of
DHA supplementation on inflammatory status and cancer cell growth.
4. Effect ofω-3 PUFAs and DHA on Insulin-Resistance and Obesity in BC
Omega-3 PUFAs are considered to play a protective role on BC risk in obese women which might
be related to increased uptake of fatty acids by the cells and to decreased inflammation and enhanced
insulin sensitivity in adipose tissue [4] (Figure 2). Increased estrogen synthesis, as a consequence of
higher aromatase expression in adipose tissue, is associated with increased obesity related BC risk [4].
High intake ofω-3 PUFAs might decrease endogenous estrogen production via inhibition of aromatase
activity/expression [4]. However, this aspect needs to be better clarified in further studies.
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Inverse associations between ω-3 PUFA dietetic intake and cancer risk have been also
reported in Asian women having a dietary intake of marine PUFAs 40 times greater than women
from Western countries, using validated questionnaires of dietary intakes [50–52]. In particular,
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Gago-Dominguez et al. administered a validated questionnaire on food frequency to Singapore Chinese
women, consisting of more than 160 food and beverage items, to assess patient’s fatty acids intake and
BC risk [50].
Chajès et al. conducted a case–control study in Mexico on 1000 patients affected by BC and over
1000 control healthy subjects to specifically investigate the relation between obesity, ω-3 PUFA intake
and BC risk [53]. It was found that an increased risk of BC associated with greaterω-6 PUFA dietary
intake in premenopause (p = 0.04) and, on the other hand, a decreased risk of BC associated with
higher ω-3 PUFA intake in obese women (p = 0.008), but not in overweight nor in normal weight
women. In particular, DHA intake in Mexican women was about 10 times lower than the one reported
in Western populations [53].
Patterson et al. showed that in BC survivors the intake of marine PUFAs related to improved BC
prognosis [14]. More than 3000 women diagnosed and treated for non-metastatic BC were considered,
documenting as higher dietary intakes of EPA and DHA were correlated with lower BC recurrence
and with a dose-dependent reduction of mortality risk in overweight women (average body mass
index of 27.3 kg/m2). From the other side, DHA and EPA intakes from fish oil supplements were not
associated with BC relapse or mortality [14].
MacLean et al. have reviewed the literature to assess the role of ω-3 PUFAs in preventing
cancer [54] and found no overall trend across different cohorts and categories of ω-3 PUFA
consumption, suggesting that lowω-3 PUFA levels might not be associated with cancer risk.
In contrast, a recent meta-analysis by Zheng et al. supports a protective role of marine derived
ω-3 PUFA on the incidence of BC [55], confirming thatω-3 PUFA intake was significantly inversely
associated with BC in postmenopausal but not in premenopausal women. This observation highlights
also that specific benefit of marine ω-3 PUFA may be obtained usually after long-term exposure.
This finding might be determined by a possible different role of premenopausal and postmenopausal
adiposity in conditioning risk of BC. One recent meta-analysis suggested that high body mass index
appears protective against premenopausal BC but it still represents a risk factor for postmenopausal
BC [56]. A mechanistic explanation of these findings is still lacking and further studies are needed.
In a French study, including approximately 56,000 women, Thiebaut et al. investigated the
relationship between individual PUFA intakes, evaluated by the administration of dietary history
questionnaires, and BC risk and found no association [57].
The Women’s Healthy Eating and Living (WHEL) was a randomized trial conducted among
more than 3000 BC survivor women, who were assigned to receive a phone call counseling program,
supplemented with cooking classes participation and promotional newsletters about diet (intervention
group), or to receive only print materials describing dietary guidelines (control group) [58]. Although
the first group significantly increased fruit and vegetables intakes and reduced fat intakes, no
differences in BC recurrence nor mortality were documented after a mean follow-up period of seven
years [58].
Interpretation of the reported data is limited by differences regarding the characteristics of the
populations studied and by differences in the methods used to assess exposure toω-3 fatty acids and
the risk of BC.
Monk et al. [4] provided findings that dietaryω-3 PUFAs, particularly marine-derived EPA and
DHA, which present anti-inflammatory properties in obesity [41] and anti-neoplastic role in BC [59,60],
may be an additional strategy in the prevention and treatment of obesity-related BC, by reducing
inflammatory status within the mammary gland.
Omega-3 PUFAs have been demonstrated to target multiple aspects of the obese BC phenotype [4].
Nutritional interventions appear able to modulate treatment toxicity in different type of cancers [11,61].
In particular, DHA supplementation during chemotherapy enhanced the toxic effects of anti-mitotic
therapies [59]. This effect was determined by the incorporation of DHA into membrane lipids, altering
membrane permeability, and improving cellular drugs uptake [59]. In this view, a clinical study
showed that DHA supplementation during chemotherapy increased survival in metastatic BC patients.
The anti-cancer property of DHA may be determined by its ability to counteract cell growth and
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facilitate apoptosis [13]. In addition, Patterson et al. indicated that BC patients with greater intakes
of EPA and DHA from food, but not from other sources such as supplements, showed a significant
dose-dependent reduction in mortality from any cause [14].
Therefore, other studies, evaluating the role of dietary PUFAs on BC risk, found inconclusive
epidemiological evidence [62]. Although several findings indicate that DHA does not present
modulating effects on insulin sensitivity, it does not exclude the possibility that DHA provides
a positive effect on insulin metabolism [63]. More importantly, obesity is a cause and consequence of
inflammation which is a key determinant in the pathogenesis of insulin resistance. Understanding
the influence of these modifiable risk factors in BC appears of high importance as they directly affect
patients’ prognosis.
5. Conclusions
The prevention and treatment of BC represent highly relevant public health issues. These aspects
are important in the research field especially regarding the relations between diet, lifestyle, and BC.
A possible preventative and therapeutic role of DHA in BC development and progression has
been highlighted. Robust data indicate several anti-inflammatory effects of DHA suggesting that this
ω-3 PUFA may represent a valid candidate for primary and secondary BC prevention in subjects at
increased risk as well as BC survivors [64]. It remains uncertain whether such biological effects of
DHA, consisting in altering inflammatory pathways, are clinically relevant at typical dietary doses.
Controversy exists regarding the potential anticancer effects of marineω-3 PUFAs and especially
DHA, and larger clinical trials appear necessary to clarify these aspects.
Table 1. Docosahexaenoic acid (DHA) in breast cancer—Key points.
Research on modifiable risk factors in breast cancer is receiving clinical relevance because they affect the
prognosis of the disease [1,2].
Data indicate that obesity increases breast cancer risk in part due to hormonal interactions and in part to
inflammatory and insulin-resistance mechanisms [3–6].
Omega-3 fatty acids are metabolically active lipids with anti-inflammatory properties [13–16].
Omega-3 fatty acids and, in particular, DHA ameliorate obesity-induced inflammation and
insulin-resistance [4,36,37].
Considering the role of inflammation in breast cancer, there is an increasing rationale for the use of DHA in
combination with anticancer therapies [14–16,64].
Additional evidence is needed to assess the protective role of DHA breast cancer.
Acknowledgments: Alessio Molfino’s work was supported in part by Umberto Veronesi Foundation, Milan, Italy
(Young Investigator Programme 2014–2015).
Author Contributions: All authors contributed to the writing and editing of this review. The final manuscript
was approved by all authors.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Ghose, A.; Kundu, R.; Toumeh, A.; Hornbeck, C.; Mohamed, I. A review of obesity, insulin resistance and
the role of exercise in breast cancer patients. Nutr. Cancer 2015, 67, 197–202. [CrossRef] [PubMed]
2. Makarem, N.; Chandran, U.; Bandera, E.V.; Parekh, N. Dietary fat in breast cancer survival. Annu. Rev. Nutr.
2013, 33, 319–348. [CrossRef] [PubMed]
3. Benedetto, C.; Salvagno, F.; Canuto, E.M.; Gennarelli, G. Obesity and female malignancies. Best Pract. Res.
Clin. Obst. Gyn. 2015, 29, 528–540. [CrossRef] [PubMed]
4. Monk, J.M.; Turk, H.F.; Liddle, D.M.; de Boer, A.A.; Power, K.A.; Ma, D.W.; Robinson, L.E. n-3
polyunsaturated fatty acids and mechanisms to mitigate inflammatory paracrine signaling in obesity-
associated breast cancer. Nutrients 2014, 6, 4760–4793. [PubMed]
Int. J. Mol. Sci. 2016, 17, 505 8 of 10
5. Ferguson, R.D.; Gallagher, E.J.; Scheinman, E.J.; Damouni, R.; LeRoith, D. The epidemiology and molecular
mechanisms linking obesity, diabetes, and cancer. Vitam. Horm. 2013, 93, 51–98. [PubMed]
6. Rose, D.P.; Vona-Davis, L. Biochemical and molecular mechanisms for the association between obesity,
chronic inflammation, and breast cancer. BioFactors 2014, 40, 1–12. [CrossRef] [PubMed]
7. Macaulay, V.M.; Nicholls, J.E.; Gledhill, J.; Rowlands, M.G.; Dowsett, M.; Ashworth, A. Biological effects of
stable overexpression of aromatase in human hormone-dependent breast cancer cells. Br. J. Cancer 1994, 69,
77–83. [CrossRef] [PubMed]
8. Simpson, E.R.; Mahendroo, M.S.; Nichols, J.E.; Bulun, S.E. Aromatase gene expression in adipose tissue:
Relationship to breast cancer. Int. J. Fertil. Menopausal Stud. 1994, 39, S75–S83.
9. Daling, J.R.; Malone, K.E.; Doody, D.R.; Johnson, L.G.; Gralow, J.R.; Porter, P.L. Relation of body mass index
to tumor markers and survival among young women with invasive ductal breast carcinoma. Cancer 2001, 92,
720–729. [CrossRef]
10. Fagherazzi, G.; Chabbert-Buffet, N.; Fabre, A.; Guillas, G.; Boutron-Ruault, M.C.; Mesrine, S.;
Clavel-Chapelon, F. Hip circumference is associated with the risk of premenopausal ER-/PR-breast cancer.
Int. J. Obes. 2012, 36, 431–439. [CrossRef] [PubMed]
11. Laviano, A.; Rianda, S.; Molfino, A.; Rossi Fanelli, F. Omega-3 fatty acid in cancer. Curr. Opin. Clin. Nutr.
Metab. Care 2013, 16, 156–161. [CrossRef] [PubMed]
12. Bougnoux, P.; Hajjaji, N.; Maheo, K.; Couet, C.; Chevalier, S. Fatty acids and breast cancer: Sensitization to
treatments and prevention of metastatic re-growth. Prog. Lipid Res. 2010, 49, 76–86. [CrossRef] [PubMed]
13. Bougnoux, P.; Hajjaji, N.; Ferrasson, M.N.; Giraudeau, B.; Couet, C.; Le, F.O. Improving outcome of
chemotherapy of metastatic breast cancer by docosahexaenoic acid: A phase II trial. Br. J. Cancer 2009, 101,
1978–1985. [CrossRef] [PubMed]
14. Patterson, R.E.; Flatt, S.W.; Newman, V.A.; Natarajan, L.; Rock, C.L.; Thomson, C.A.; Caan, B.J.; Parker, B.A.;
Pierce, J.P. Marine fatty acid intake is associated with breast cancer prognosis. J. Nutr. 2011, 141, 201–206.
[CrossRef] [PubMed]
15. Makhoul, Z.; Kristal, A.R.; Gulati, R.; Luick, B.; Bersamin, A.; Boyer, B.; Mohatt, G.V. Associations of very
high intakes of eicosapentaenoic and docosahexaenoic acids with biomarkers of chronic disease risk among
Yup’ik Eskimos. Am. J. Clin. Nutr. 2011, 91, 777–785. [CrossRef] [PubMed]
16. Alfano, C.M.; Imayama, I.; Neuhouser, M.L.; Kiecolt-Glaser, J.K.; Smith, A.W.; Meeske, K.; McTiernan, A.;
Bernstein, L.; Baumgartner, K.B.; Ulrich, C.M.; et al. Fatigue, inflammation, andω-3 andω-6 fatty acid intake
among breast cancer survivors. J. Clin. Oncol. 2012, 30, 1280–1287. [CrossRef] [PubMed]
17. Fay, M.; Freedman, L.; Clifford, C.; Midthune, D. Effect of different types and amounts of fat on the
development of mammary tumors in rodents: A review. Cancer Res. 1997, 57, 3979–3988. [PubMed]
18. Carmichael, A.R. Obesity and prognosis of breast cancer. Obes. Rev. 2006, 7, 333–340. [CrossRef] [PubMed]
19. DeSantis, C.; Siegel, R.; Bandi, P.; Jemal, A. Breast cancer statistics, 2011. CA Cancer J. Clin. 2011, 61, 409–418.
[CrossRef] [PubMed]
20. Chlebowski, R.T.; Aiello, E.; McTiernan, A. Weight loss in breast cancer patient management. J. Clin. Oncol.
2002, 20, 1128–1143. [CrossRef] [PubMed]
21. Chlebowski, R.T. Nutrition and physical activity influence on breast cancer incidence and outcome. Breast
2013, 22, 30–37. [CrossRef] [PubMed]
22. Rooney, M.; Wald, A. Interventions for the management of weight and body composition changes in women
with breast cancer. Clin. J. Oncol. Nurs. 2007, 11, 41–52. [CrossRef] [PubMed]
23. Chan, D.S.; Norat, T. Obesity and breast cancer: not only a risk factor of the disease. Curr. Treat. Opt. Oncol.
2015, 16. [CrossRef] [PubMed]
24. Heideman, W.H.; Russell, N.S.; Gundy, C.; Rookus, M.A.; Voskuil, D.W. The frequency, magnitude and
timing of post-diagnosis body weight gain in Dutch breast cancer survivors. Eur. J. Cancer 2009, 45, 119–126.
[CrossRef] [PubMed]
25. Ibrahim, E.M.; Al-Homaidh, A. Physical activity and survival after breast cancer diagnosis: Meta-analysis of
published studies. Med. Oncol. 2011, 28, 753–765. [CrossRef] [PubMed]
26. Patterson, R.E.; Cadmus, L.A.; Emond, J.A.; Pierce, J.P. Physical activity, diet, adiposity and female breast
cancer prognosis: A review of the epidemiologic literature. Maturitas 2010, 66, 5–15. [CrossRef] [PubMed]
27. Bradshaw, P.T.; Ibrahim, J.G.; Stevens, J.; Cleveland, R.; Abrahamson, P.E.; Satia, J.A.; Teitelbaum, S.L.;
Neugut, A.I.; Gammon, M.D. Postdiagnosis change in bodyweight and survival after breast cancer diagnosis.
Epidemiology 2012, 23, 320–327. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2016, 17, 505 9 of 10
28. Howe, L.R.; Subbaramaiah, K.; Hudis, C.A.; Dannenberg, A.J. Molecular pathways: Adipose inflammation
as a mediator of obesity-associated cancer. Clin. Cancer Res. 2013, 19, 6074–6083. [CrossRef] [PubMed]
29. Baumgarten, S.C.; Frasor, J. Inflammation: An instigator of more aggressive estrogen receptor (ER) positive
breast cancers. Mol. Endocrinol. 2012, 26, 360–371. [CrossRef] [PubMed]
30. Grivennikov, S.I.; Karin, M. Inflammatory cytokines in cancer: Tumour necrosis factor and interleukin 6 take
the stage. Ann. Rheum. Dis. 2011, 70, i104–i108. [CrossRef] [PubMed]
31. Horng, T.; Hotamisligil, G.S. Linking the inflammasome to obesity-related disease. Nat. Med. 2011, 17,
164–165. [CrossRef] [PubMed]
32. Hotamisligil, G.S. Inflammation and metabolic disorders. Nature 2006, 444, 860–867. [CrossRef] [PubMed]
33. Pasanisi, P.; Berrino, F.; de Petris, M.; Venturelli, E.; Mastroianni, A.; Panico, S. Metabolic syndrome as
a prognostic factor for breast cancer recurrences. Int. J. Cancer 2006, 119, 236–238. [CrossRef] [PubMed]
34. Widjaja, A.; Stratton, I.M.; Horn, R.; Holman, R.R.; Turner, R.; Brabant, G. UKPDS 20: Plasma leptin, obesity,
and plasma insulin in type 2 diabetic subjects. J. Clin. Endocrinol. Metab. 1997, 82, 654–657. [CrossRef]
[PubMed]
35. Jarde, T.; Caldefie-Chezet, F.; Damez, M.; Mishellany, F.; Penault-Llorca, F.; Guillot, J.; Vasson, M.P. Leptin
and leptin receptor involvement in cancer development: A study on human primary breast carcinoma.
Oncol. Rep. 2008, 19, 905–911. [CrossRef] [PubMed]
36. Simopoulos, A.P. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed. Pharmacother.
2002, 56, 365–379. [CrossRef]
37. Kalupahana, N.S.; Claycombe, K.; Newman, S.J.; Stewart, T.; Siriwardhana, N.; Matthan, N.;
Lichtenstein, A.H.; Moustaid-Moussa, N. Eicosapentaenoic acid prevents and reverses insulin resistance
in high-fat diet-induced obese mice via modulation of adipose tissue inflammation. J. Nutr. 2010, 140,
1915–1922. [CrossRef] [PubMed]
38. Laviano, A.; Seelaender, M.; Sanchez-Lara, K.; Gioulbasanis, I.; Molfino, A.; Rossi Fanelli, F.
Beyond anorexia-cachexia. Nutrition and modulation of cancer patients’ metabolism: Supplementary,
complementary or alternative anti-neoplastic therapy? Eur. J. Pharmacol. 2011, 668, s87–s90. [CrossRef]
[PubMed]
39. Park, J.; Morley, T.S.; Kim, M.; Clegg, D.J.; Scherer, P.E. Obesity and cancer—Mechanisms underlying tumour
progression and recurrence. Nat. Rev. Endocrinol. 2014, 10, 455–465. [CrossRef] [PubMed]
40. Bouwens, M.; van de Rest, O.; Dellschaft, N.; Bromhaar, M.G.; de Groot, L.C.; Geleijnse, J.M.; Muller, M.;
Afman, L.A. Fish-oil supplementation induces antiinflammatory gene expression profiles in human blood
mononuclear cells. Am. J. Clin. Nutr. 2009, 90, 415–424. [CrossRef] [PubMed]
41. Puglisi, M.J.; Hasty, A.H.; Saraswathi, V. The role of adipose tissue in mediating the beneficial effects of
dietary fish oil. J. Nutr. Biochem. 2011, 22, 101–108. [CrossRef] [PubMed]
42. Flock, M.R.; Skulas-Ray, A.C.; Harris, W.S.; Gaugler, T.L.; Fleming, J.A.; Kris-Etherton, P.M. Effects of
supplemental long-chain omega-3 fatty acids and erythrocyte membrane fatty acid content on circulating
inflammatory markers in a randomized controlled trial of healthy adults. Prostaglandins Leukot. Essent.
Fatty Acids 2014, 91, 161–168. [CrossRef] [PubMed]
43. Wall, R.; Ross, R.P.; Fitzgerald, G.F.; Stanton, C. Fatty acids from fish: The anti-inflammatory potential of
long-chain omega-3 fatty acids. Nutr. Rev. 2010, 68, 280–289. [CrossRef] [PubMed]
44. Simopoulos, A.P. An increase in the omega-6/omega-3 fatty acid ratio increases the risk for obesity. Nutrients
2016, 2. [CrossRef] [PubMed]
45. Hawkins, R.A.; Sangster, K.; Arends, M.J. Apoptotic death of pancreatic cancer cells induced by
polyunsaturated fatty acids varies with double bond number and involves an oxidative mechanism. J. Pathol.
1998, 185, 61–70. [CrossRef]
46. Grammatikos, S.I.; Subbaiah, P.V.; Victor, T.A.; Miller, W.M. n-3 and n-6 fatty acid processing and growth
effects in neoplastic and non-cancerous human mammary epithelial cell lines. Br. J. Cancer 1994, 70, 219–227.
[CrossRef] [PubMed]
47. Gonzalez, M.J.; Schemmel, R.A.; Dugan, L., Jr.; Gray, J.I.; Welsch, C.W. Dietary fish oil inhibits human breast
carcinoma growth: A function of increased lipid peroxidation. Lipids 1993, 28, 827–832. [CrossRef] [PubMed]
48. Roy, J.; le Guennec, J.Y.; Galano, J.M.; Thireau, J.; Bultel-Poncé, V.; Demion, M.; Oger, C.; Lee, J.C.; Durand, T.
Non-enzymatic cyclic oxygenated metabolites of omega-3 polyunsaturated fatty acid: Bioactive drugs?
Biochimie 2016, 120, 56–61. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2016, 17, 505 10 of 10
49. Roy, J.; Oliveira, L.T.; Oger, C.; Galano, J.M.; Bultel-Poncé, V.; Richard, S.; Guimaraes, A.G.; Vilela, J.M.;
Andrade, M.S.; Durand, T.; et al. Polymeric nanocapsules prevent oxidation of core-loaded molecules:
Evidence based on the effects of docosahexaenoic acid and neuroprostane on breast cancer cells proliferation.
J. Exp. Clin. Cancer Res. 2015, 34. [CrossRef] [PubMed]
50. Gago-Dominguez, M.; Yuan, J.M.; Sun, C.L.; Lee, H.P.; Yu, M.C. Opposing effects of dietary n-3 and n-6 fatty
acids on mammary carcinogenesis: The Singapore Chinese Health Study. Br. J. Cancer 2003, 89, 1686–1692.
[CrossRef] [PubMed]
51. Hirose, K.; Takezaki, T.; Hamajima, N.; Miura, S.; Tajima, K. Dietary factors protective against breast cancer
in Japanese premenopausal and postmenopausal women. Int. J. Cancer 2003, 107, 276–282. [CrossRef]
[PubMed]
52. Wakai, K.; Tamakoshi, K.; Date, C.; Fukui, M.; Suzuki, S.; Lin, Y.; Niwa, Y.; Nishio, K.; Yatsuya, H.;
Kondo, T.; et al. Dietary intakes of fat and fatty acids and risk of breast cancer: A prospective study
in Japan. Cancer Sci. 2005, 96, 590–599. [CrossRef] [PubMed]
53. Chajes, V.; Torres-Mejía, G.; Biessy, C.; Ortega-Olvera, C.; Angeles-Llerenas, A.; Ferrari, P.; Lazcano-Ponce, E.;
Romieu, I.ω-3 andω-6 polyunsaturated fatty acid intakes and the risk of breast cancer in Mexican women:
Impact of obesity status. Cancer Epidemiol. Biomark. Prev. 2011, 21, 319–326. [CrossRef] [PubMed]
54. MacLean, C.H.; Newberry, S.J.; Mojica, W.A.; Khanna, P.; Issa, A.M.; Suttorp, M.J.; Lim, Y.W.; Traina, S.B.;
Hilton, L.; Garland, R.; et al. Effects of omega-3 fatty acids on cancer risk: A systematic review. JAMA
2006, 295, 403–415. [CrossRef] [PubMed]
55. Zheng, J.S.; Hu, X.J.; Zhao, Y.M.; Yang, J.; Li, D. Intake of fish and marine n-3 polyunsaturated fatty acids and
risk of breast cancer: Meta-analysis of data from 21 independent prospective cohort studies. BMJ 2013, 346.
[CrossRef] [PubMed]
56. Cheraghi, Z.; Poorolajal, J.; Hashem, T.; Esmailnasab, N.; Doosti Irani, A. Effect of body mass index on breast
cancer during premenopausal and postmenopausal periods: A meta-analysis. PLoS ONE 2012, 7, e51446.
[CrossRef] [PubMed]
57. Thiebaut, A.C.; Chajes, V.; Gerber, M.; Boutron-Ruault, M.C.; Joulin, V.; Lenoir, G.; Berrino, F.; Riboli, E.;
Benichou, J.; Clavel-Chapelon, F. Dietary intakes of omega-6 and omega-3 polyunsaturated fatty acids and
the risk of breast cancer. Int. J. Cancer 2009, 124, 924–931. [CrossRef] [PubMed]
58. Pierce, J.P.; Natarajan, L.; Caan, B.J.; Parker, B.A.; Greenberg, E.R.; Flatt, S.W.; Rock, C.L.; Kealey, S.;
Al-Delaimy, W.K.; Bardwell, W.A.; et al. Influence of a diet very high in vegetables, fruit, and fiber and low
in fat on prognosis following treatment for breast cancer: The Women’s Healthy Eating and Living (WHEL)
randomized trial. JAMA 2007, 298, 289–298. [CrossRef] [PubMed]
59. Menendez, J.A.; Lupu, R.; Colomer, R. Exogenous supplementation with omega-3 polyunsaturated fatty
acid docosahexaenoic acid (DHA; 22:6n-3) synergistically enhances taxane cytotoxicity and downregulates
Her-2/neu (c-erbB-2) oncogene expression in human breast cancer cells. Eur. J. Cancer Prev. 2005, 14, 263–270.
[CrossRef] [PubMed]
60. MacLennan, M.B.; Clarke, S.E.; Perez, K.; Wood, G.A.; Muller, W.J.; Kang, J.X.; Ma, D.W. Mammary tumor
development is directly inhibited by lifelong n-3 polyunsatured fatty acids. J. Nutr. Biochem. 2013, 24,
388–395. [CrossRef] [PubMed]
61. Laviano, A.; Molfino, A.; Rossi Fanelli, F. Cancer treatment toxicity: Can nutrition help? Nat. Rev. Clin. Oncol.
2012, 9. [CrossRef] [PubMed]
62. McCullough, M.L.; Giovannucci, E.L. Diet and cancer prevention. Oncogene 2004, 23, 6349–6364. [CrossRef]
[PubMed]
63. Flock, M.R.; Rogers, C.J.; Prabhu, K.S.; Kris-Etherton, P.M. Immunometabolic role of long-chain omega-3 fatty
acids in obesity-induced inflammation. Diabetes Metab. Res. Rev. 2013, 29, 431–445. [CrossRef] [PubMed]
64. Fabian, C.J.; Kimler, B.F.; Hursting, S.D. Omega-3 fatty acids for breast cancer prevention and survivorship.
Breast Cancer Res. 2015, 17. [CrossRef] [PubMed]
© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons by Attribution
(CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
